{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:58:15Z","timestamp":1754161095109,"version":"3.41.2"},"reference-count":26,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443293269"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.podrm.2023.11.002","type":"book-chapter","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T07:45:59Z","timestamp":1701935159000},"page":"19-40","source":"Crossref","is-referenced-by-count":0,"title":["Duvelisib: A comprehensive profile"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.podrm.2023.11.002_bib1","unstructured":"Website: \u3008http:\/\/www.chemspider.com\/Chemical-Structure.28637766.html?rid=86c58620-519c-47b8\u20138add-7254eab2e32a&page_num=0#synonymsTab\u3009 (accessed February 3, 2023)."},{"key":"10.1016\/bs.podrm.2023.11.002_bib2","unstructured":"Website: \u3008https:\/\/go.drugbank.com\/drugs\/DB11952\u3009 (accessed February 3, 2023)."},{"key":"10.1016\/bs.podrm.2023.11.002_bib3","unstructured":"Website: \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/50905713\u3009 (accessed February 3, 2023)."},{"key":"10.1016\/bs.podrm.2023.11.002_bib4","unstructured":"Website \u3008https:\/\/www.selleckchem.com\/datasheet\/ipi-145-ink1197-S702802-DataSheet.html\u3009 (accessed February 3, 2023)."},{"key":"10.1016\/bs.podrm.2023.11.002_bib5","unstructured":"Website: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211155Orig1Orig2s000MultidisciplineR.pdf\u3009 (accessed February 3, 2023)."},{"key":"10.1016\/bs.podrm.2023.11.002_bib6","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/bs.podrm.2023.11.002_bib7","unstructured":"U.S. Food & Drug Administration (FDA), Duvelisib (Copiktra, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Maryland, 2018. Available from: \u3008https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm621503.htm\u3009 (accessed February 3, 2023)."},{"key":"10.1016\/bs.podrm.2023.11.002_bib8","unstructured":"L. Leah, Duvelisib granted priority review for R\/R CLL\/SLL and FL. Cancer Network, 2018. Website: \u3008https:\/\/www.cancernetwork.com\/view\/duvelisib-granted-priority-review-rr-cllsll-and-fl\u3009 (accessed February 3, 2023)."},{"key":"10.1016\/bs.podrm.2023.11.002_bib9","unstructured":"P. Ren, Y. Liu, T.E. Wilson, L. Li, K. Chan, C. Rommel. Certain Chemical Entities, Compositions and Methods. US2009312319A1, 14 December 2009."},{"key":"10.1016\/bs.podrm.2023.11.002_bib10","unstructured":"P. Ren, Y. Liu, T.E. Wilson, L. Li, K. Chan, C. Rommel, Certain Chemical Entities, Compositions and Methods. WO2011008302A1, January 20, 2011."},{"key":"10.1016\/bs.podrm.2023.11.002_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2021.120287","article-title":"Synthesis, spectroscopic and computational studies on hydrogen bonded charge transfer complex of duvelisib with chloranilic acid: application to development of novel 96-microwell spectrophotometric assay","volume":"264","author":"Darwish","year":"2022","journal-title":"Spectrochim. Acta. A. Mol. Biomol. Spectrosc."},{"key":"10.1016\/bs.podrm.2023.11.002_bib12","doi-asserted-by":"crossref","first-page":"10624","DOI":"10.3390\/app122010624","article-title":"Development and validation of 96-microwell-based spectrophotometric and high-performance liquid chromatography with fluorescence detection methods with high throughput for quantitation of duvelisib and seliciclib in their bulk forms and capsules","volume":"12","author":"Aljohar","year":"2022","journal-title":"Appl. Sci."},{"key":"10.1016\/bs.podrm.2023.11.002_bib13","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.3390\/app122010460","article-title":"Development and validation of a novel microwell-based fluorimetric method assisted with fluorescence plate reader for high-throughput determination of duvelisib: application to the analysis of capsules and plasma samples","volume":"12","author":"Al-Hossaini","year":"2022","journal-title":"Appl. Sci."},{"key":"10.1016\/bs.podrm.2023.11.002_bib14","first-page":"99","article-title":"Analytlcal quality by design approach in RP-HPLC method development and validation for the estimation of duvelisib","volume":"14","author":"Srujani","year":"2021","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"10.1016\/bs.podrm.2023.11.002_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5015","article-title":"Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: application to a pharmacokinetic study in rats","volume":"35","author":"Siddesh","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/bs.podrm.2023.11.002_bib16","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2147\/DDDT.S318714","article-title":"A highly sensitive nonextraction-assisted HPLC method with fluorescence detection for quantification of duvelisib in plasma samples and its application to pharmacokinetic study in rats","volume":"15","author":"Sayed","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/bs.podrm.2023.11.002_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13318-017-0402-5","article-title":"Prediction of tissue-to-plasma ratios of basic compounds in mice","volume":"42","author":"Nigade","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/bs.podrm.2023.11.002_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113355","article-title":"Development of a novel and quick UPLC-MS\/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs","volume":"187","author":"Shao","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2023.11.002_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5530\/ijper.56.1.34","article-title":"Establishment of a rapid and highly sensitive reverse-phase high-performance liquid chromatography based analytical assay method for duvelisib","volume":"56","author":"Sonawane","year":"2022","journal-title":"Indian J. Pharm. Edu. Res."},{"key":"10.1016\/bs.podrm.2023.11.002_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/22297928.2021.1895885","article-title":"Validated LC-MS\/MS method for simultaneous quantitation of three PI3K inhibitors, copanlisib, duvelisib and idelalisib in mouse plasma: application to a pharmacokinetic study in mice","volume":"11","author":"Gabani","year":"2021","journal-title":"Anal. Chem. Lett."},{"key":"10.1016\/bs.podrm.2023.11.002_bib21","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1039\/D3RA00310H","article-title":"Development and validation of an UPLC-ESI-MS\/MS method for quantification of duvelisib in plasma: application to pharmacokinetic study in rats","volume":"13","author":"Darwish","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/bs.podrm.2023.11.002_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105579","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/bs.podrm.2023.11.002_bib23","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: first global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/bs.podrm.2023.11.002_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.podrm.2023.11.002_bib25","unstructured":"Drugs.com. Duvelisib. Website: \u3008https:\/\/www.drugs.com\/monograph\/duvelisib.html\u3009 (accessed February 3, 2023)."},{"key":"10.1016\/bs.podrm.2023.11.002_bib26","unstructured":"Center for Drug Evaluation and Research, Multi-disciplinary review and evaluation copiktra. Website: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211155Orig1Orig2s000MultidisciplineR.pdf\u3009 (accessed February 3, 2023)."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512523000146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512523000146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:14:50Z","timestamp":1753715690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512523000146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443293269"],"references-count":26,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2023.11.002","relation":{},"ISSN":["1871-5125"],"issn-type":[{"type":"print","value":"1871-5125"}],"subject":[],"published":{"date-parts":[[2024]]}}}